Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Izotropic ( (TSE:IZO) ) has issued an update.
Izotropic has been recognized in Research and Markets’ latest report, which analyzes the U.S. breast cancer screening and diagnostic market, projected to grow from $1.55 billion in 2024 to $2.34 billion by 2030. This inclusion supports Izotropic’s regulatory strategy for its IzoView Breast CT device, suggesting a high demand for new breast imaging technologies and positioning the company for potential rapid market adoption.
More about Izotropic
Izotropic Corporation is a medical device company focused on commercializing imaging-based products using innovative and emerging technologies for more accurate screening, diagnosis, and treatment of breast cancers.
YTD Price Performance: 160.0%
Average Trading Volume: 50,043
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $6.51M
For an in-depth examination of IZO stock, go to TipRanks’ Stock Analysis page.
